• Home
  • News
  • Calendar
  • About DF/HCC
  • Membership
  • Visitor Center

New or renewed collaborative grants

Despite current funding constraints, the NIH continues to award funding to a number of DF/HCC research initiatives. Recently, these awards included one program project grant (P01) and one Specialized Center Grant (P50). For more details, click below.

1P01CA120964-01A1 PI: Kwiatkowski, David J,
Molecular Pathogenesis of the Hamartoma Syndromes

The goals of this research proposal are to elucidate the molecular signaling pathways that contribute to tumor development and physiology in the hamartoma syndromes resulting from loss of the tumor suppressor genes TSC1, TSC2, LKB1, and PTEN, and to identify and explore potential therapeutic targets. This research will provide insight into the pathogenesis of tuberous sclerosis complex (TSC), Peutz-Jeghers syndrome (PJS), and the variety of PTEN syndromes (e.g., Cowden disease), and will also have broader implications since the pathways these tumor suppressors control are activated in the majority of the common adult malignancies.

1 P50 HG004233-01 PI: Vidal, Marc
Genomic Analysis of Network Perturbations in Human Disease

The goal of this proposal is to better understand cellular networks based on environmental and genetic perturbations of network structure and readout of the effects using interactome mapping, proteomic analysis, and transcriptional profiling. Using a defined model system with a variety of disease outcomes, we will explore the concept that one must understand changes in complex cellular networks to fully understand the link between genotype, environment, and phenotype. By integrating observations from network-level perturbations caused by particular viruses together with genome-wide human variation datasets for related human diseases, we will focus on developing general principles for data integration and network prediction, instantiation of these in open-source software tools, and development of testable hypotheses that can be used to assess the value of our methods.